All Stories

  1. Traditional Dietary Patterns and Risk of Mortality in a Longitudinal Cohort of the Salus in Apulia Study
  2. The association of patient-reported symptoms and clinical and lung function parameters in patients with chronic obstructive pulmonary disease in stable phase
  3. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
  4. Relationship between Inflammatory Food Consumption and Age-Related Hearing Loss in a Prospective Observational Cohort: Results from the Salus in Apulia Study
  5. Time to test antibacterial therapy in Alzheimer’s disease
  6. Do BACE inhibitor failures in Alzheimer patients challenge the amyloid hypothesis of the disease?
  7. Power Doppler Ultrasound Findings before and after Focused Extracorporeal Shock Wave Therapy for Achilles Tendinopathy: A Pilot Study on Pain Reduction and Neovascularization Effect
  8. Disease-modifying therapies for tauopathies: agents in the pipeline
  9. Hydroxytryptamine transporter gene-linked polymorphic region (5HTTLPR) is associated with delusions in Alzheimer’s disease
  10. Amyloid-β immunotherapy for alzheimer disease: Is it now a long shot?
  11. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
  12. Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life
  13. BACE inhibitors in clinical development for the treatment of Alzheimer’s disease
  14. Social Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE Study
  15. Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review
  16. Executive Dysfunction Detected with the Frontal Assessment Battery in Alzheimer’s Disease Versus Vascular Dementia
  17. Association of Antidementia Drugs and Mortality in Community-Dwelling Frail Older Patients With Dementia: The Role of Mortality Risk Assessment
  18. Sensory Changes and the Hearing Loss–Cognition Link
  19. Can a cognitive rehabilitation program in early stages of Parkinson's disease improve cognition, apathy and brain functional connectivity for up to 18 months?
  20. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults
  21. Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging
  22. The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset
  23. Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?
  24. Phytochemicals in the Treatment of Alzheimer's Disease: A Systematic Review
  25. Cognitive frailty: a potential target for secondary prevention of dementia
  26. Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry
  27. Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer’s Disease and Late-Life Cognitive Disorders: A Systematic Review
  28. Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity
  29. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease
  30. Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline
  31. Long-term safety of repeated high doses of incobotulinumtoxinA injections for the treatment of upper and lower limb spasticity after stroke
  32. An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-term Care Facilities
  33. Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer’s Disease
  34. Change in Coefficient of Fatigability Following Rapid, Repetitive Movement Training in Post-Stroke Spastic Paresis: A Prospective Open-Label Observational Study
  35. Information and Communication Technologies for the Activities of Daily Living in Older Patients with Dementia: A Systematic Review
  36. Emerging biomarkers and screening for cognitive frailty
  37. Clinical and genetic analyses of familial and sporadic frontotemporal dementia patients in Southern Italy
  38. Anti-tau vaccine in Alzheimer's disease: a tentative step
  39. Genetics of tailored medicine: Focus on CNS drugs
  40. Three Decades of Comprehensive Geriatric Assessment: Evidence Coming From Different Healthcare Settings and Specific Clinical Conditions
  41. Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging
  42. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants
  43. Bipolar Disorder and Frontotemporal Dementia: An Intriguing Association
  44. Relation of Statin Use and Mortality in Community-Dwelling Frail Older Patients With Coronary Artery Disease
  45. Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?
  46. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
  47. Non-Pharmacological Approaches in the Treatment of Dementia
  48. Is Extracorporeal Shockwave Therapy Combined With Isokinetic Exercise More Effective Than Extracorporeal Shockwave Therapy Alone for Subacromial Impingement Syndrome? A Randomized Clinical Trial
  49. Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy
  50. A Validation Study of Vascular Cognitive Impairment Genetics Meta-Analysis Findings in an Independent Collaborative Cohort
  51. Daily Function as Predictor of Dementia in Cognitive Impairment, No Dementia (CIND) and Mild Cognitive Impairment (MCI): An 8-Year Follow-Up in the ILSA Study
  52. Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders
  53. High doses of incobotulinumtoxinA for the treatment of post-stroke spasticity: are they safe and effective?
  54. Warfarin Treatment and All-Cause Mortality in Community-Dwelling Older Adults with Atrial Fibrillation: A Retrospective Observational Study
  55. The Role of Hearing Impairment in Cognitive Decline: Need for the Special Sense Assessment in Evaluating Cognition In Older Age
  56. Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants
  57. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants
  58. Shared genetic contribution to ischemic stroke and Alzheimer's disease
  59. Time to generalization and prediction of survival in patients with amyotrophic lateral sclerosis: a retrospective observational study
  60. Delusions in Patients with Alzheimer’s Disease: A Multidimensional Approach
  61. Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium
  62. Tau aggregation inhibitors: the future of Alzheimer’s pharmacotherapy?
  63. Klotho Gene and Selective Serotonin Reuptake Inhibitors: Response to Treatment in Late-Life Major Depressive Disorder
  64. Examination of level of knowledge in Italian general practitioners attending an education session on diagnosis and management of the early stage of Alzheimer's disease: pass or fail?
  65. Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients
  66. Pharmacogenetics in Neurodegenerative Diseases: Implications for Clinical Trials
  67. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease
  68. Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson’s Disease? The Potential Role of Zolpidem in the Treatment of Parkinson’s Disease
  69. Alternative pharmacological treatment options for agitation in Alzheimer’s disease
  70. Cognitive Frailty: A Systematic Review of Epidemiological and Neurobiological Evidence of an Age-Related Clinical Condition
  71. Role of CYP2D6 Polymorphisms in the Outcome of Postoperative Pain Treatment
  72. Progresses in treating agitation: a major clinical challenge in Alzheimer’s disease
  73. Frontal assessment battery for detecting executive dysfunction in amyotrophic lateral sclerosis without dementia: a retrospective observational study
  74. Targeting Cognitive Frailty: Clinical and Neurobiological Roadmap for a Single Complex Phenotype
  75. Coffee Consumption Habits and the Risk of Mild Cognitive Impairment: The Italian Longitudinal Study on Aging
  76. Ultrasound-Guided Injection of Botulinum Toxin Type A for Piriformis Muscle Syndrome: A Case Report and Review of the Literature
  77. Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331 288 participants
  78. Statin Treatment and Mortality in Community-Dwelling Frail Older Patients with Diabetes Mellitus: A Retrospective Observational Study
  79. Age-related hearing impairment and frailty in Alzheimer's disease: interconnected associations and mechanisms
  80. Time to generalisation as a predictor of prognosis in amyotrophic lateral sclerosis: Table 1
  81. Measuring pharmacogenetics in special groups: geriatrics
  82. Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life
  83. A novel Alzheimer disease locus located near the gene encoding tau protein
  84. Employment of higher doses of botulinum toxin type A to reduce spasticity after stroke
  85. Age-related hearing impairment—a risk factor and frailty marker for dementia and AD
  86. Epidemiology of age related hearing loss: A review
  87. Perspective: The Challenge of Clinical Decision-Making for Drug Treatment in Older People. The Role of Multidimensional Assessment and Prognosis
  88. Postural and Balance Disorders in Patients with Parkinson’s Disease: A Prospective Open-Label Feasibility Study with Two Months of Action Observation Treatment
  89. Italian Frontotemporal Dementia Network (FTD Group-SINDEM): sharing clinical and diagnostic procedures in Frontotemporal Dementia in Italy
  90. Sniff nasal inspiratory pressure as a prognostic factor of tracheostomy or death in amyotrophic lateral sclerosis
  91. Convergent genetic and expression data implicate immunity in Alzheimer's disease
  92. A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease
  93. Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: A systematic review
  94. Caregiver burden characterization in patients with Alzheimer's disease or vascular dementia
  95. Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques
  96. Plant-Based Nutraceutical Interventions against Cognitive Impairment and Dementia: Meta-Analytic Evidence of Efficacy of a Standardized Gingko biloba Extract
  97. Prevalence of diabetes and depressive symptomatology and their effect on mortality risk in elderly Italians: The Italian Longitudinal Study on Aging
  98. Possible role of alpha-lipoic acid in the treatment of peripheral nerve injuries
  99. Nutrition, frailty, and Alzheimer's disease
  100. Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment
  101. Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease
  102. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return?
  103. Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease
  104. Adhesive taping vs. daily manual muscle stretching and splinting after botulinum toxin type A injection for wrist and fingers spastic overactivity in stroke patients: a randomized controlled trial
  105. Prevention of Late-life Cognitive Disorders: Diet-Related Factors, Dietary Patterns, and Frailty Models
  106. An intrinsically safe facility for forefront research and training on nuclear technologies — A zero-power experiment
  107. Is there still any hope for amyloid-based immunotherapy for Alzheimerʼs disease?
  108. Extracorporeal Shock Wave Therapy for the Treatment of Poststroke Plantar-Flexor Muscles Spasticity: A Prospective Open-Label Study
  109. Hippocampal atrophy in people with memory deficits: results from the population-based IPREA study
  110. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward
  111. Mediterranean Diet and Cognitive Decline. A Lesson from the Whole-Diet Approach: What Challenges Lie Ahead?
  112. The Prevalence of Peripheral and Central Hearing Impairment and Its Relation to Cognition in Older Adults
  113. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease
  114. Incidence of dementia: evidence for an effect modification by gender. The ILSA Study
  115. Neutron flux characterization of the SM1 sub-critical multiplying complex of the Pavia University
  116. The Global Cardiovascular Risk Transition: Associations of Four Metabolic Risk Factors with National Income, Urbanization, and Western Diet in 1980 and 2008
  117. SBOTE Study: Extracorporeal Shock Wave Therapy Versus Electrical Stimulation After Botulinum Toxin Type A Injection for Post-Stroke Spasticity–A Prospective Randomized Trial
  118. The Serotonin Transporter Gene Locus in Late-Life Major Depressive Disorder
  119. Frailty syndrome and the risk of vascular dementia: The Italian Longitudinal Study on Aging
  120. Forkhead-box-O1 locus y marcadores metabólicos en los ancianos: estudio de asociación
  121. Treatment of Late-Life Major Depressive Disorder With Selective Serotonin Reuptake Inhibitors Improves the Multidimensional Prognostic Index
  122. Erratum: Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease
  123. TOMM40, APOE, and APOC1 in Primary Progressive Aphasia and Frontotemporal Dementia
  124. Efficacy and safety of higher doses of botulinum toxin type A NT 201 free from complexing proteins in the upper and lower limb spasticity after stroke
  125. Vascular factors predict polyneuropathy in a non-diabetic elderly population
  126. Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimer’s disease patients
  127. Current Epidemiological Approaches to the Metabolic-Cognitive Syndrome
  128. Neuropsychiatric Symptoms and Functional Status in Alzheimer’s Disease and Vascular Dementia Patients
  129. Effectiveness of the Frequency Rhythmic Electrical Modulation System for the Treatment of Chronic and Painful Venous Leg Ulcers in Older Adults
  130. Changes in severity of depressive symptoms and mortality: the Italian Longitudinal Study on Aging
  131. A Multidimensional Prognostic Index in Common Conditions Leading to Death in Older Patients
  132. The metabolic syndrome, incidence of diabetes and mortality among the elderly: The Italian Longitudinal Study of Ageing
  133. Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease
  134. Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective?
  135. Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies
  136. Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease
  137. Addition of the Multidimensional Prognostic Index to the Estimated Glomerular Filtration Rate Improves Prediction of Long-Term All-Cause Mortality in Older Patients with Chronic Kidney Disease
  138. Comparing the Prognostic Accuracy for All-Cause Mortality of Frailty Instruments: A Multicentre 1-Year Follow-Up in Hospitalized Older Patients
  139. The Serotonin Transporter Gene Locus in Late-Life Major Depressive Disorder
  140. Usefulness of the multidimensional prognostic index (MPI) in the management of older patients with chronic kidney disease
  141. Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease
  142. Effectiveness of Switching Therapy from Complexing Protein-containing Botulinum Toxin Type A to a Formulation with Low Immunogenicity in Spasticity after Stroke: A case report
  143. Treatment of Upper Limb Spasticity after Stroke: One-Year Safety and Efficacy of Botulinum Toxin Type A NT201
  144. Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging
  145. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease
  146. Interacting with γSecretase for Treating Alzheimer's Disease: From Inhibition to Modulation
  147. Anti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab
  148. Metabolic syndrome, mild cognitive impairment, and progression to dementia. The Italian Longitudinal Study on Aging
  149. Metabolic syndrome as a risk factor for neurological disorders
  150. Effect of botulinum toxin type A and modified constraint-induced movement therapy on motor function of upper limb in children with obstetrical brachial plexus palsy
  151. The Genetics of the Human APOE Polymorphism
  152. Glycerophospholipids and glycerophospholipid-derived lipid mediators: A complex meshwork in Alzheimer’s disease pathology
  153. Different models of frailty in predementia and dementia syndromes
  154. A Multidimensional Prognostic Index (MPI) based on a comprehensive geriatric assessment predicts short- and long-term all-cause mortality in older hospitalized patients with transient ischemic attack
  155. Pharmacogenetics in Geriatric Medicine: Challenges and Opportunities for Clinical Practice
  156. Metabolic Syndrome, Mild Cognitive Impairment and Dementia
  157. Mediterranean Diet in Predementia and Dementia Syndromes
  158. γ-secretase inhibitors for treating Alzheimer’s disease: rationale and clinical data
  159. Klotho locus, metabolic traits, and serum hemoglobin in hospitalized older patients: a genetic association analysis
  160. Late-life depression and Alzheimer's disease: The glutamatergic system inside of this mirror relationship
  161. APOE and Alzheimer disease: a major gene with semi-dominant inheritance
  162. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads
  163. The APOE Gene Locus in Frontotemporal Dementia and Primary Progressive Aphasia
  164. Diet and Alzheimer’s disease risk factors or prevention: the current evidence
  165. Frailty syndrome and all-cause mortality in demented patients: the Italian Longitudinal Study on Aging
  166. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease
  167. Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations
  168. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants
  169. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants
  170. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3·0 million participants
  171. Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?
  172. Alcohol Consumption in Predementia and Dementia Syndromes
  173. Dietary Fatty Acids, Cognitive Decline, and Dementia
  174. Aluminium in the Diet, Cognitive Decline and Dementia
  175. Neuropsychiatric Symptoms, Endophenotypes, and Syndromes in Late-Onset Alzheimer's Disease: Focus on APOE Gene
  176. Polymorphisms in GlutathioneS-Transferase Omega-1 Gene and Increased Risk of Sporadic Alzheimer Disease
  177. PLASMA LIPID DISTURBANCES AND COGNITIVE DECLINE
  178. Nutraceutical Properties of Mediterranean Diet and Cognitive Decline: Possible Underlying Mechanisms
  179. Angiotensin-converting enzyme (ACE) genotypes and disability in hospitalized older patients
  180. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease
  181. PLASMA LEVELS OF N-3 POLYUNSATURATED FATTY ACIDS AND COGNITIVE DECLINE: POSSIBLE ROLE OF DEPRESSIVE SYMPTOMS AND APOLIPOPROTEIN E GENOTYPING
  182. Alcohol consumption and cardiovascular risk factors in older lifelong wine drinkers: The Italian Longitudinal Study on Aging
  183. The APOE polymorphism in Alzheimer's disease patients with neuropsychiatric symptoms and syndromes
  184. Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease
  185. Pharmacogenetics of cytochrome P450 (CYP) in the elderly
  186. Dietary Patterns and Protection Against Alzheimer Disease and Cognitive Decline
  187. Prevalence of Aging-Associated Cognitive Decline in an Italian elderly population: results from cross-sectional phase of Italian PRoject on Epidemiology of Alzheimer’s disease (IPREA)
  188. The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study
  189. Peripheral Antioxidant Markers in Mild Cognitive Impairment and its Progression to Dementia
  190. Metabolic Syndrome and Cognitive Impairment: Current Epidemiology and Possible Underlying Mechanisms
  191. Dietary Unsaturated Fatty Acids and Risk of Mild Cognitive Impairment
  192. Effectiveness of botulinum toxin type A treatment of neck pain related to nocturnal bruxism: a case report
  193. Is Insulin Resistant Brain State a Central Feature of the Metabolic-Cognitive Syndrome?
  194. Effect of botulinum toxin type A, motor imagery and motor observation on motor function of hemiparetic upper limb after stroke
  195. REVIEW: γ‐Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State
  196. Apolipoprotein E-related all-cause mortality in hospitalized elderly patients
  197. Dietary fatty acids in dementia and predementia syndromes: Epidemiological evidence and possible underlying mechanisms
  198. Aluminum in the Diet and Alzheimer's Disease: From Current Epidemiology to Possible Disease-Modifying Treatment
  199. Interleukin 6–174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease
  200. Late-Life Depression, Mild Cognitive Impairment, and Dementia: Possible Continuum?
  201. Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid
  202. EFFECT OF DONEPEZIL ON THE CONTINUUM OF DEPRESSIVE SYMPTOMS, MILD COGNITIVE IMPAIRMENT, AND PROGRESSION TO DEMENTIA
  203. Polymorphism C in the Serotonin Transporter Gene in Depression-Free Elderly Patients with Vascular Dementia
  204. Are NSAIDs useful to treat Alzheimer’s disease or mild cognitive impairment?
  205. Effect of intrathecal baclofen, botulinum toxin type A and a rehabilitation programme on locomotor function after spinal cord injury: A case report
  206. Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing
  207. All-Cause Mortality and Competing Risks of Fatal and Nonfatal Vascular Events in the Italian Longitudinal Study on Aging: Impact of Lipoprotein(a)
  208. Beyond the neurotransmitter-focused approach in treating Alzheimer’s Disease: drugs targeting β-amyloid and tau protein
  209. Alcohol consumption and metabolic syndrome in the elderly: results from the Italian longitudinal study on aging
  210. Botulinum Toxin Type a in the Treatment of Painful Adductor Muscle Contracture After Total Hip Arthroplasty
  211. Whole-Diet Approach: Working on a Criterion Validity for Age-Related Cognitive Decline and Mild Cognitive Impairment
  212. Botulinum toxin type A and a rehabilitation program in the treatment of Pisa syndrome in Parkinson’s disease
  213. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
  214. Alpha-2-macroglobulin gene, oxidized low-density lipoprotein receptor-1 locus, and sporadic Alzheimer's disease
  215. The Multidimensional Prognostic Index (MPI), Based on a Comprehensive Geriatric Assessment Predicts Short- and Long-Term Mortality in Hospitalized Older Patients with Dementia
  216. Temporal Relationship between Depressive Symptoms and Cognitive Impairment: The Italian Longitudinal Study on Aging
  217. Disease-Modifying Approach to the Treatment of Alzheimerʼs Disease
  218. Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease
  219. Botulinum Toxin Type A in the Treatment of Focal Hand Dystonia After Surgical Treatment for Thumb Duplication
  220. Mediterranean Dietary Pattern, Mild Cognitive Impairment, and Progression to Dementia
  221. Short-term Effects of High-Intensity Laser Therapy Versus Ultrasound Therapy in the Treatment of People With Subacromial Impingement Syndrome: A Randomized Clinical Trial
  222. Alcohol Drinking, Cognitive Functions in Older Age, Predementia, and Dementia Syndromes
  223. POSSIBLE PREDICTORS OF VASCULAR COGNITIVE IMPAIRMENT–NO DEMENTIA
  224. APOLIPOPROTEIN E, DEMENTIA, AND HUMAN LONGEVITY
  225. Higher total cholesterol, cognitive decline, and dementia
  226. Moderate Alcohol Consumption, Apolipoprotein E, and Neuroprotection
  227. Possible Role of S-Adenosylmethionine, S-Adenosylhomocysteine, and Polyunsaturated Fatty Acids in Predementia Syndromes and Alzheimer's Disease
  228. Physical Disability and Depressive Symptomatology in an Elderly Population: A Complex Relationship. The Italian Longitudinal Study on Aging (ILSA)
  229. Dietary Fatty Acids and Predementia Syndromes
  230. N-3 polyunsaturated fatty acids and statins in heart failure
  231. Polyunsaturated Fatty Acid and S-Adenosylmethionine Supplementation in Predementia Syndromes and Alzheimer's Disease: A Review
  232. Role of Biphosphonates and Lymphatic Drainage Type Leduc in the Complex Regional Pain Syndrome (Shoulder–Hand Syndrome)
  233. RESPONSE LETTER TO DR. MELO ET AL.
  234. Acoustic analysis of swallowing sounds: A new technique for assessing dysphagia
  235. Cognitive behavioural group therapy in mild cognitive impairment: Intervention with a cognitive or behavioural/psychological focus?
  236. Diabetes as a Risk Factor for Cognitive Decline in Older Patients
  237. Predementia and Dementia Syndromes: Possible Role of Lipoprotein Metabolism
  238. Hypertension and Mild Cognitive Impairment Subtypes
  239. BEYOND CORONARY ARTERY DISEASE: ROSUVASTATIN IN OLDER PATIENTS WITH ISCHEMIC SYSTOLIC HEART FAILURE
  240. MILD COGNITIVE IMPAIRMENT: DEMENTIA RISK FACTOR OR HIGH-RISK STATE FOR PROGRESSION TO DEMENTIA?
  241. Impact of depressive symptoms on the rate of progression to dementia in patients affected by mild cognitive impairment. The Italian Longitudinal Study on Aging
  242. Dietary fatty acids, age-related cognitive decline, and mild cognitive impairment
  243. Vascular risk factors, alcohol intake, and cognitive decline
  244. Alcohol Use, Thiamine Deficiency, and Cognitive Impairment
  245. The RELN Locus in Alzheimer's Disease
  246. Polymorphism C in the serotonin transporter gene (SLC6A4) in questionable dementia and Alzheimer's disease
  247. BOTULINUM TOXIN TYPE A IN THE TREATMENT OF SIALORRHEA IN PARKINSON'S DISEASE
  248. S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in predementia syndromes and Alzheimer's disease
  249. Association Analysis of GRIN2B, Encoding N-Methyl-D-Aspartate Receptor 2B Subunit, and Alzheimer’s Disease
  250. Short arm of chromosome 11 and sporadic Alzheimer's disease: Catalase and cathepsin D gene polymorphisms
  251. Calcium metabolism and vitamin D in the extreme longevity
  252. Depressive Symptoms, Vascular Risk Factors and Mild Cognitive Impairment
  253. Lifestyle-related factors in predementia and dementia syndromes
  254. Botulinum toxin type A and type B for sialorrhoea in Parkinson's disease: A case for switching therapy?
  255. CIND AND MCI IN THE ITALIAN ELDERLY: FREQUENCY, VASCULAR RISK FACTORS, PROGRESSION TO DEMENTIA
  256. Lipoproteins, Vascular-Related Genetic Factors, and Human Longevity
  257. Interleukin 6 Variable Number of Tandem Repeats (VNTR) Gene Polymorphism in Centenarians
  258. LIFESTYLE-RELATED FACTORS, ALCOHOL CONSUMPTION, AND MILD COGNITIVE IMPAIRMENT
  259. Heterogeneity of mild cognitive impairment and other predementia syndromes in progression to dementia
  260. CHANGE OF DIAGNOSES IN PROBABLE AND POSSIBLE MILD COGNITIVE IMPAIRMENT: THE ITALIAN LONGITUDINAL STUDY ON AGING
  261. Progression to Dementia in Probable and Possible Mild Cognitive Impairment
  262. Differences in allele frequencies of ACE I/D polymorphism between Northern and Southern Europe at different ages
  263. Incident Occurrence of Depressive Symptoms among Patients with Mild Cognitive Impairment – The Italian Longitudinal Study on Aging
  264. Alcohol consumption, mild cognitive impairment, and progression to dementia
  265. EFFECT OF A CLINICAL STROKE ON THE RISK OF DEMENTIA IN A PROSPECTIVE COHORT
  266. Ten-year risk of dementia in subjects with mild cognitive impairment
  267. Whole-Diet Approach, Mediterranean Diet, and Alzheimer Disease
  268. Apolipoprotein E Genotypes in Hospitalized Elderly Patients with Vascular Dementia
  269. Mild cognitive impairment: Risk of Alzheimer disease and rate of cognitive decline
  270. DIETARY POLYUNSATURATED FATTY ACID SUPPLEMENTATION, PREDEMENTIA SYNDROMES, AND ALZHEIMER'S DISEASE
  271. Possible Role of Unsaturated Fatty Acids in a 14-Day Healthy Longevity Lifestyle Program
  272. The Missing ApoE Allele
  273. TOTAL CHOLESTEROL LEVELS AND THE RISK OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE
  274. Mediterranean diet, mild cognitive impairment, and Alzheimer’s disease
  275. APOLIPOPROTEIN E GENOTYPES IN MILD COGNITIVE IMPAIRMENT SUBTYPES
  276. DIET, CHOLESTEROL METABOLISM, AND ALZHEIMER'S DISEASE: APOLIPOPROTEIN E AS A POSSIBLE LINK?
  277. Macronutrients, aluminium from drinking water and foods, and other metals in cognitive decline and dementia
  278. Adherence to a Mediterranean dietary pattern and risk of Alzheimer's disease
  279. Dietary intake of unsaturated fatty acids and age-related cognitive decline: A 8.5-year follow-up of the Italian Longitudinal Study on Aging
  280. Current knowledge of chromosome 12 susceptibility genes for late-onset Alzheimer's disease
  281. WHOLE-DIET APPROACH AND RISK OF CHRONIC DISEASE: LIMITS AND ADVANTAGES
  282. Low incidence for predementia and dementia syndromes in a brain imaging study
  283. Cardiovascular Factors and Cognitive Impairment: A Role for Unsaturated Fatty Acids and Mediterranean Diet?
  284. Efficacy and tolerability of combined treatment with l-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus
  285. Stroke and Memory Decline: A Question of Degenerative or Vascular Origin
  286. Serum total cholesterol as a biomarker for Alzheimer’s disease: Mid-life or late-life determinations?
  287. PREVALENCE RATES OF MILD COGNITIVE IMPAIRMENT SUBTYPES AND PROGRESSION TO DEMENTIA
  288. Sex Differences in the Association of Apolipoprotein E and Angiotensin-Converting Enzyme Gene Polymorphisms With Healthy Aging and Longevity: A Population-Based Study From Southern Italy
  289. Lipid metabolism in cognitive decline and dementia
  290. Predementia and Dementia Syndromes: Possible Role of Lipoprotein Metabolism
  291. Cognitive frailty: Predementia syndrome and vascular risk factors
  292. Dietary fatty acids intakes and rate of mild cognitive impairment. The Italian Longitudinal Study on Aging
  293. Cerebrovascular disease in the elderly: lipoprotein metabolism and cognitive decline
  294. Nutritional factors, cognitive decline, and dementia
  295. Circulating biomarkers of cognitive decline and dementia
  296. Candidate genes for late-onset Alzheimer's disease: Focus on chromosome 12
  297. Current Epidemiology of Mild Cognitive Impairment and Other Predementia Syndromes
  298. The Cathepsin D Gene Exon 2 (C224T) Polymorphism and Sporadic Alzheimer's Disease in European Populations
  299. Dietary fatty acids intake: possible role in cognitive decline and dementia
  300. Unsaturated fatty acids intake and all-causes mortality: a 8.5-year follow-up of the Italian Longitudinal Study on Aging
  301. Polymorphisms in the Oxidized Low-Density Lipoprotein Receptor-1 Gene and Risk of Alzheimer's Disease
  302. Italian Project on Epidemiology of Alzheimer’s disease (I.PR.E.A.): study design and methodology of cross-sectional survey
  303. Molecular Determinants of Human Longevity
  304. Vascular risk factors, incidence of MCI, and rates of progression to dementia
  305. Interleukin 6-174 G/C promoter gene polymorphism and sporadic Alzheimer's disease: geographic allele and genotype variations in Europe
  306. Mediterranean diet and cognitive decline
  307. Interleukin 6 −174 G/C promoter gene polymorphism in centenarians: no evidence of association with human longevity or interaction with apolipoprotein E alleles
  308. Vascular genetic factors and human longevity
  309. Regional European differences in allele and genotype frequencies of low density lipoprotein receptor-related protein 1 polymorphism in Alzheimer's disease
  310. Vascular risk and genetics of sporadic late-onset Alzheimer’s disease
  311. Semantic Dementia: Neuropsychological and Behavioral Patterns in Relation to Hemispheric Asymmetries
  312. Semantic Dementia
  313. Angiotensin I converting enzyme (ACE) gene polymorphism in centenarians: Different allele frequencies between the North and South of Europe
  314. Shifts in angiotensin I converting enzyme insertion allele frequency across Europe: implications for Alzheimer's disease risk
  315. Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer’s disease patients and centenarians
  316. Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease
  317. Selective Attention Skills in Differentiating between Alzheimer's Disease and Normal Aging
  318. Relation of lipoprotein(a) as coronary risk factor to type 2 diabetes mellitus and low-density lipoprotein cholesterol in patients ≥65 years of age (The Italian Longitudinal Study on Aging)
  319. Symbol Cancellation Test
  320. Apolipoprotein and antiotensin converting enzyme genes: regional differences and extreme longevity in Europe
  321. F175S Change and a Novel Polymorphism in Presenilin-1 Gene in Late-Onset Familial Alzheimer’s Disease
  322. Lack of association between ace polymorphism and Alzheimer's disease in southern Italy
  323. Lipoprotein(a) in the elderly: beyond atherosclerosis
  324. Serum apoliprotein E levels in alzheimer's disease and extreme longevity
  325. Analysis of individual items of mini-mental state examination in discrimination between normal and demented subjects
  326. Impact of decreased frequency of apolipoprotein E ε4 allele on Alzheimer's disease in Southern Italy
  327. Apolipoprotein E in Southern Italy: protective effect of ε2 allele in early- and late-onset sporadic Alzheimer's disease
  328. Lipoprotein(A) affects cognitive function in the elderly. The Italian longitudinal study on aging
  329. Lipoprotein(A) is a risk factor for Alzheimer's disease independently of apolipoprotein E genotype
  330. Decreased frequency of apolipoprotein E ε4 allele from Northern to Southern Europe in Alzheimer's disease patients and centenarians
  331. High monounsaturated fatty acids intake protects against age-related cognitive decline
  332. Efficacy of Cytidine Diphosphate Choline in Patients Affected by Chronic Cerebrovascular Disease
  333. Analysis of some aspects of learning and memorization processes in an adult population
  334. Correlation between neuropsychometric tests and semiquantitative evaluation of the regional cerebral blood flow (RCBF) in a group of outpatients affected by cognitive impairment
  335. Impact of aging on the relationships between impairment of “Orientation” and “Recall” items of MMSE and mild to moderate mood disorders
  336. Abstract